https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40865 12 years of age with a chronic cough due to asthma or NAEB. Eligible studies were identified in MEDLINE, CENTRAL, and SCOPUS and assessed for relevance and quality. Guidelines were developed and voted upon using CHEST guideline methodology. Results: Of the citations reviewed, 3/1,175, 53/656, and 6/134 were identified as being eligible for inclusion in the three systematic reviews, respectively. In contrast to established guidelines for asthma therapies in general and the inclusion in some guidelines for a role of biomarkers of airway inflammation to guide treatment in severe disease, the evidence of specific benefit related to the use of non-invasive biomarkers in patients with chronic cough due to asthma was weak. The best therapeutic option for cough in asthma or NAEB is inhaled corticosteroids followed by leukotriene receptor antagonism. Conclusions: This guideline offers recommendations on the role of non-invasive measurements of airway inflammation and treatment for cough due to asthma or NAEB based on the available literature, and identifies gaps in knowledge and areas for future research.]]> Tue 19 Jul 2022 14:10:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25578 Sat 24 Mar 2018 07:35:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39031 1 as have pericytes² and endothelial-mesenchymal transition.^3,4 However, the most studied mechanism is epithelial-mesenchymal transition (EMT), in which epithelial cells lose epithelial characteristics and become more mesenchymal, gaining mobility and enhanced ability to secrete ECM. This highly dynamic process has been subcategorized according to the three main functions it is associated with: embryonic development (type I), wound healing and tissue repair (type II), and cancer (type III). In this translational review, the mechanisms, roles, and impact of EMT (particularly type II) in chronic lung diseases are discussed. We also evaluate whether current medications influence EMT and how we may affect this process in the future.]]> Mon 29 Jan 2024 17:51:32 AEDT ]]>